Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,969.84

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $2,969.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $11.0112/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297449 CMS
Allergan, Inc. $13.7912/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297447 CMS
Eisai Inc. $11.7511/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751251443 CMS
Avanir Pharmaceuticals, Inc. $13.5311/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722217817 CMS
Allergan, Inc. $3.5411/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297445 CMS
Allergan, Inc. $13.9911/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297441 CMS
Allergan, Inc. $14.3511/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297443 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0510/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278815 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.4610/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278813 CMS
Allergan, Inc. $6.9910/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297439 CMS
Eisai Inc. $11.2010/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751232851 CMS
Allergan, Inc. $14.7409/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297437 CMS
Allergan, Inc. $3.2509/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297435 CMS
Otsuka America Pharmaceutical, Inc. $13.5209/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748770079 CMS
Allergan, Inc. $11.0409/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297433 CMS
Allergan, Inc. $1,320.0009/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297431 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7409/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278811 CMS
Allergan, Inc. $13.6108/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297429 CMS
Merck Sharp & Dohme Corporation $13.9708/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747688207 CMS
Allergan, Inc. $12.5908/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297427 CMS
Otsuka America Pharmaceutical, Inc. $13.5208/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748770075 CMS
Allergan, Inc. $13.1208/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297425 CMS
Allergan, Inc. $10.5807/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297423 CMS
Allergan, Inc. $9.4807/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297421 CMS
Allergan, Inc. $7.8706/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297419 CMS
Allergan, Inc. $14.1204/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297417 CMS
Allergan, Inc. $13.9903/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297415 CMS
Jazz Pharmaceuticals Inc. $14.0902/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745453123 CMS
Allergan, Inc. $1.3902/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297413 CMS
Allergan, Inc. $1,300.0002/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297411 CMS
Allergan, Inc. $1.2501/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297409 CMS
Allergan, Inc. $12.3201/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297407 CMS
Teva Pharmaceuticals USA, Inc. $12.9901/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749467415 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $13,626.20 12/31/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
M23-894 ABBV-932 Ph 2 BPD No dispute reported 06/30/2026 1100766133
Principal investigator 1 ABBVIE INC. $450.00 12/31/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
M23-714 Ubrelvy Menstrual Migraine No dispute reported 06/30/2026 1100766135
Principal investigator 1 ABBVIE INC. $600.00 12/31/2024 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
M22-721 ABBV-916 Ph 1-2 MAD with POC in AD No dispute reported 06/30/2026 1100766137
Principal investigator 1 Eisai Inc. $10,200.00 12/18/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529225
Principal investigator 1 Eisai Inc. $49,512.60 12/18/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529229
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 12/18/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1143157140
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,568.82 12/09/2024 Non-covered Recipient Entity
Biology Behavioral Health
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1155489396
Principal investigator 1 Eisai Inc. $1,626.30 11/20/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529227
Principal investigator 1 ABBVIE INC. $12,000.00 11/07/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1100753727
Principal investigator 1 BioXcel Therapeutics, Inc. $295,925.10 10/16/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1150029819
Principal investigator 1 BioXcel Therapeutics, Inc. $3,275.17 10/16/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1150029821
Principal investigator 1 Boehringer Ingelheim International GmbH $4,617.16 09/01/2024 Non-covered Recipient Entity
Bio-Behavioral Health
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1101071339
Principal investigator 1 Eisai Inc. $4,320.00 08/21/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529221
Principal investigator 1 Eisai Inc. $2,762.10 07/25/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529219
Principal investigator 1 BioXcel Therapeutics, Inc. $26,855.80 07/24/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1150029785
Principal investigator 1 BioXcel Therapeutics, Inc. $737,275.80 07/24/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1150029787
Principal investigator 1 ABBVIE INC. $15,000.00 07/05/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100727154
Principal investigator 1 Eisai Inc. $11,827.80 07/03/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529223
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $150.00 05/30/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143126510
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $25,560.57 04/26/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143125819
Principal investigator 1 Eisai Inc. $27,415.80 04/24/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529215
Principal investigator 1 BioXcel Therapeutics, Inc. $630,416.70 04/19/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1150029729
Principal investigator 1 BioXcel Therapeutics, Inc. $487,892.70 03/01/2024 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1150029689
Principal investigator 1 BioXcel Therapeutics, Inc. $487,892.70 03/01/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1150029693
Principal investigator 1 Eisai Inc. $5,047.20 01/26/2024 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529217
Principal investigator 1 Eli Lilly and Company $1,125.96 01/25/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137354680
Principal investigator 1 BioXcel Therapeutics, Inc. $276,592.50 01/12/2024 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1150029661
Principal investigator 1 Eli Lilly and Company $49,325.00 01/02/2024 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137355350